HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA – Free Report) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $74.00 target price on the biotechnology company’s stock.
Separately, SVB Leerink began coverage on XOMA in a report on Monday, April 29th. They issued an outperform rating and a $40.00 price target on the stock.
Read Our Latest Report on XOMA
XOMA Trading Down 2.6 %
XOMA (NASDAQ:XOMA – Get Free Report) last released its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The business had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. Equities analysts forecast that XOMA will post -2.11 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in XOMA stock. BNP Paribas Financial Markets boosted its holdings in shares of XOMA Co. (NASDAQ:XOMA – Free Report) by 55.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,543 shares of the biotechnology company’s stock after purchasing an additional 1,266 shares during the period. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 as of its most recent SEC filing. 95.92% of the stock is owned by institutional investors.
XOMA Company Profile
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
See Also
- Five stocks we like better than XOMA
- Buy P&G Now, Before It Sets A New All-Time High
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Insider Trades May Not Tell You What You Think
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- How to Most Effectively Use the MarketBeat Earnings Screener
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.